Alfasigma has acquired the marketing rights for Jyseleca, a JAK1 inhibitor drug used for rheumatoid arthritis and ulcerative colitis, following European Medicines Agency approval. This acquisition...
Authorities are focusing on addressing challenges related to integrating AI tools. The first initiative involves supporting AI in the life cycle of medicines. The Committee for...
The European Union plans to become an important point for clinical trials. The work plan is structured according to the ten ACT EU priority actions and...